Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC
June 13th 2023The combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered as triplet therapy in patients with PD-L1–high, metastatic non–small cell lung cancer.
Read More
Phase 1 Data Support Further Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma
June 12th 2023The FGFR2 inhibitor RLY-4008 generated early evidence of efficacy in patients with cholangiocarcinoma harboring FGFR2 fusions, according to findings from the phase 1/2 ReFocus trial, which were presented at the 2023 ASCO Annual Meeting.
Read More
Panitumumab Plus Trifluridine-Tipiracil Improves Outcomes in RAS Wild-type mCRC
May 31st 2023The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.
Read More
PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment Options
May 31st 2023Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.
Read More
Shifts In Ovarian Cancer Treatment Options Necessitate Continued Research
May 29th 2023Whitfield B. Growdon, MD, discusses the role PARP inhibitors have played in ovarian cancer since their introduction to the field, the updated clinical trial data that contributed to the indication withdrawals for these agents, and where future research in this area may be headed.
Read More
Advances in Precision Medicine Propel Personalized GI Cancer Care
May 25th 2023Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.
Read More
METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL
May 24th 2023Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.
Read More
Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer
May 23rd 2023Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.
Read More
Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors
May 23rd 2023Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.
Read More
Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma
May 19th 2023Polymorphic alleles of ABCB1 or VEGF were predictive of lenalidomide efficacy in patients with mantle cell lymphoma who received lenalidomide maintenance after autologous stem cell transplant.
Read More
MAJIC-PV Trial Confirms Clinical Benefit of Ruxolitinib in Polycythemia Vera
May 19th 2023Treatment with ruxolitinib generated superior responses vs treatment with best available therapy in patients with hydroxycarbamide-intolerant or -resistant polycythemia vera, according to findings from the phase 2 MAJIC-PV trial.
Read More
Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis
May 19th 2023Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.
Read More
Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population
May 18th 2023Abemaciclib plus endocrine therapy delivered sustained survival benefits with a tolerable safety profile when used as adjuvant treatment in Chinese patients with high-risk, hormone receptor–positive, HER2-negative early breast cancer.
Read More
Tamibarotene/Azacitidine Combination Under Investigation in Higher-risk MDS
May 3rd 2023Ana Alfonso Piérola, MD, PhD, discusses the rationale for targeting retinoic acid receptor alpha in patients with higher-risk myelodysplastic syndrome, the goals of the SELECT MDS-1 trial investigating tamibarotene, and where the future of research and treatment for this patient population is headed.
Read More
CLDN18.2 Testing May Influence Advances in the Gastric Cancer Treatment Paradigm
May 2nd 2023Kevin M. Waters, MD, PhD, discusses key findings from a study that reinforced the rationale for Claudin18.2 testing, the prevalence of this protein in gastric cancers, and how this potential therapeutic target represents the evolving role of pathology in cancer diagnosis and care.
Read More
Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC
April 29th 2023Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Read More
Uproleselan Combinations Contribute to Robust Investigational Profile in AML
April 27th 2023Michael Andreeff, MD, PhD, discusses the potential benefits of E-selectin inhibition in the AML tumor microenvironment, data that have contributed to the further development of uproleselan in this population, and additional AML targets under investigation that may broaden the treatment landscape.
Read More
Tamibarotene, Azacitidine, and Venetoclax May Strengthen AML Armamentarium
April 27th 2023Brian Ball, MD, discusses the significance of targeting RARA in AML, the rationale for SELECT-AML-1, and additional AML research that may contribute to the broadening treatment paradigm in the future.
Read More
Durvalumab Plus Chemo Is Tolerable in Real-World Representative ES-SCLC Population
April 25th 2023First-line durvalumab plus up to 6 cycles of platinum and etoposide is safe and tolerable with signals of clinical efficacy consistent with those previously seen in patients with treatment-naïve extensive-stage small cell lung cancer.
Read More
Sugemalimab Monotherapy Has Clinical Benefit in NK/T-Cell Lymphoma
April 24th 2023The PD-L1 inhibitor sugemalimab produced durable responses with a tolerable safety profile in patients with relapsed/refractory natural killer/T-cell lymphoma, according to findings from a preplanned primary analysis of the multicenter, single-arm, phase 2 GEMSTONE-201 trial.
Read More
Endoscopic Strategies Broaden the Pancreatic Cancer Diagnostic and Treatment Paradigms
April 20th 2023In pancreatic cancer, the role of the endoscopist continues to evolve as technologies like endoscopic ultrasound–guided biopsies present clinicians with increasingly accurate information to characterize the tumor microenvironments of individual patients and determine effective targeted therapies.
Read More
RLY-2608 Shows Broad Therapeutic Potential in PIK3CA-Mutant Solid Tumors
April 19th 2023RLY-2608 led to sustained target inhibition with minimal effect on glucose homeostasis, acceptable safety, and antitumor activity in patients with PIK3CA-mutant solid tumors, according to interim data from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial.
Read More